88 related articles for article (PubMed ID: 10995806)
1. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer.
Tang X; Khuri FR; Lee JJ; Kemp BL; Liu D; Hong WK; Mao L
J Natl Cancer Inst; 2000 Sep; 92(18):1511-6. PubMed ID: 10995806
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients.
Tozawa T; Tamura G; Honda T; Nawata S; Kimura W; Makino N; Kawata S; Sugai T; Suto T; Motoyama T
Cancer Sci; 2004 Sep; 95(9):736-40. PubMed ID: 15471559
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Takahashi N; Shimazaki Y; Motoyama T
Cancer Sci; 2003 Jul; 94(7):589-92. PubMed ID: 12841866
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia.
Waki T; Tamura G; Sato M; Terashima M; Nishizuka S; Motoyama T
Cancer Sci; 2003 Apr; 94(4):360-4. PubMed ID: 12824905
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies.
Nakatsuka S; Takakuwa T; Tomita Y; Hoshida Y; Nishiu M; Yamaguchi M; Nishii K; Yang WI; Aozasa K
Cancer Sci; 2003 Jan; 94(1):87-91. PubMed ID: 12708480
[TBL] [Abstract][Full Text] [Related]
6.
Seok Y; Lee WK; Park JY; Kim DS
Mol Cells; 2019 Feb; 42(2):161-165. PubMed ID: 30726660
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review.
Song X; Shi K; Zhou SJ; Yu DP; Liu Z; Han Y
Drug Des Devel Ther; 2016; 10():1345-54. PubMed ID: 27103788
[TBL] [Abstract][Full Text] [Related]
8. Association of promoter methylation of
Din Shah NU; Ali MN; Ganai BA; Mudassar S; Khan MS; Kour J; Waza AA; Rasool MT; Lone AM
Heliyon; 2020 Feb; 6(2):e03488. PubMed ID: 32140600
[TBL] [Abstract][Full Text] [Related]
9. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer.
Rollin J; Iochmann S; Bléchet C; Hubé F; Régina S; Guyétant S; Lemarié E; Reverdiau P; Gruel Y
Br J Cancer; 2005 Feb; 92(4):775-83. PubMed ID: 15685245
[TBL] [Abstract][Full Text] [Related]
10. Polymerase chain reaction - surface-enhanced Raman spectroscopy (PCR-SERS) method for gene methylation level detection in plasma.
Li X; Yang T; Li CS; Song Y; Wang D; Jin L; Lou H; Li W
Theranostics; 2020; 10(2):898-909. PubMed ID: 31903158
[TBL] [Abstract][Full Text] [Related]
11. Genetic determinants for promoter hypermethylation in the lungs of smokers: a candidate gene-based study.
Leng S; Stidley CA; Liu Y; Edlund CK; Willink RP; Han Y; Landi MT; Thun M; Picchi MA; Bruse SE; Crowell RE; Van Den Berg D; Caporaso NE; Amos CI; Siegfried JM; Tesfaigzi Y; Gilliland FD; Belinsky SA
Cancer Res; 2012 Feb; 72(3):707-15. PubMed ID: 22139380
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor-suppressing kinase.
Brognard J; Zhang YW; Puto LA; Hunter T
Cancer Res; 2011 Apr; 71(8):3152-61. PubMed ID: 21487036
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of IFNG in CD4(+) T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression.
Wang F; Xu J; Zhu Q; Qin X; Cao Y; Lou J; Xu Y; Ke X; Li Q; Xie E; Zhang L; Sun R; Chen L; Fang B; Pan S
PLoS One; 2013; 8(11):e79064. PubMed ID: 24244422
[TBL] [Abstract][Full Text] [Related]
14. Is there clinical value to prognostic signatures in early-stage NSCLC?
Bunn PA; Hirsch FR; Aisner DL
Clin Cancer Res; 2014 Apr; 20(7):1727-9. PubMed ID: 24583801
[TBL] [Abstract][Full Text] [Related]
15. Is there a relationship between neural EGFL like 1 (NELL1) promoter hypermethylation and prognosis of gastric cancer?
Gao C; Liu H; Zhao Y; Miao X; Zheng H
Med Hypotheses; 2021 Oct; 158():110723. PubMed ID: 34753006
[TBL] [Abstract][Full Text] [Related]
16. The BATTLE trial: personalizing therapy for lung cancer.
Kim ES; Herbst RS; Wistuba II; Lee JJ; Blumenschein GR; Tsao A; Stewart DJ; Hicks ME; Erasmus J; Gupta S; Alden CM; Liu S; Tang X; Khuri FR; Tran HT; Johnson BE; Heymach JV; Mao L; Fossella F; Kies MS; Papadimitrakopoulou V; Davis SE; Lippman SM; Hong WK
Cancer Discov; 2011 Jun; 1(1):44-53. PubMed ID: 22586319
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Taplin ME; Regan MM; Ko YJ; Bubley GJ; Duggan SE; Werner L; Beer TM; Ryan CW; Mathew P; Tu SM; Denmeade SR; Oh WK; Sartor O; Mantzoros CS; Rittmaster R; Kantoff PW; Balk SP
Clin Cancer Res; 2009 Nov; 15(22):7099-105. PubMed ID: 19887483
[TBL] [Abstract][Full Text] [Related]
18. Clonal genetic alterations in the lungs of current and former smokers.
Mao L; Lee JS; Kurie JM; Fan YH; Lippman SM; Lee JJ; Ro JY; Broxson A; Yu R; Morice RC; Kemp BL; Khuri FR; Walsh GL; Hittelman WN; Hong WK
J Natl Cancer Inst; 1997 Jun; 89(12):857-62. PubMed ID: 9196251
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation in lung cancer.
Ramazi S; Daddzadi M; Sahafnejad Z; Allahverdi A
MedComm (2020); 2023 Dec; 4(6):e401. PubMed ID: 37901797
[TBL] [Abstract][Full Text] [Related]
20. An Update on Potential Molecular Biomarkers of Dietary Phytochemicals Targeting Lung Cancer Interception and Prevention.
Peter RM; Chou PJ; Shannar A; Patel K; Pan Y; Dave PD; Xu J; Sarwar MS; Kong AT
Pharm Res; 2023 Nov; 40(11):2699-2714. PubMed ID: 37726406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
